For the Inventor, By the Inventor

Enter assignee name

Las Vegas, NV, United States of America

Alderbio Holdings LLC

USPTO Granted Patents = 98

% Expired Patents = 45.9

EPO Patents = 12

Forward Citations = 1,049

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

John A Latham (69 out of 125 patents)

Jeffrey T L Smith (67 out of 95 patents)

Leon F Garcia-Martinez (59 out of 89 patents)

4. Benjamin H Dutzar (44 out of 72 patents)

5. Ethan Wayne Ojala (37 out of 65 patents)

6. Brian Robert Kovacevich (36 out of 68 patents)

7. Katie Olson Anderson (28 out of 38 patents)

8. Anne Elisabeth Carvalho Jensen (18 out of 21 patents)

9. Patricia Dianne McNeill (16 out of 45 patents)

10. Mark Litton (16 out of 20 patents)

11. Randall Schatzman (15 out of 26 patents)

12. Danielle Mitchell (14 out of 25 patents)

13. Jens J Billgren (12 out of 30 patents)

14. Pei Fan (11 out of 34 patents)

15. Andrew Lawrence Feldhaus (11 out of 28 patents)

Core Competencies:

Anti-IL-6

Anti-CGRP

Anti-NGF

Therapeutics

Antibodies

Cachexia

Inflammation

Diarrhea

Pain Treatment

Thrombosis

Arthritis

HGF

98 patents: Sort by Forward Citations

1. 10858424 - Anti-IL-6 antibodies for the treatment of arthritis (2020-12-08),

2. 10765746 - Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels (2020-09-08),

3. 10759853 - Antibodies to IL-6 and use thereof (2020-09-01),

4. 10640560 - Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and /or fever (2020-05-05),

5. 10550180 - Anti-ACTH antibodies and use thereof (2020-02-04),

6. 10544214 - Humanized anti-ACTH antibodies and use thereof (2020-01-28),

7. 10533048 - Anti-CGRP compositions and use thereof (2020-01-14),

8. 10471143 - Antagonists of IL-6 to raise albumin and/or lower CRP (2019-11-12),

9. 10457727 - Methods of preventing inflammation and treating pain using anti-NGF compositions (2019-10-29),

10. 10391169 - Method of treating allergic asthma with antibodies to IL-6 (2019-08-27),

11. 10344086 - Antibodies to IL-6 and use thereof (2019-07-09),

12. 10344083 - Anti-NGF compositions and use thereof (2019-07-09),

13. 10266587 - Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers (2019-04-23),

14. 10259885 - Anti-PCSK9 antibodies and use thereof (2019-04-16),

15. 10259883 - Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy (2019-04-16),

Company Overview

Alderbio Holdings LLC, based in Las Vegas, NV, specializes in the development of innovative antibody therapeutics targeting critical health issues. The company focuses on advanced treatments for conditions related to inflammation, cachexia, and gastrointestinal disorders, utilizing its expertise in anti-IL-6, anti-CGRP, and anti-NGF antibodies. Alderbio is committed to addressing unmet medical needs through its research and development efforts, aiming to improve patient outcomes in various therapeutic areas.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

98 Patents

#16 in Las Vegas, NV

#27 in Nevada

#3,859 in US

#7,930 in the World

Las Vegas, NV, United States of America

Alderbio Holdings LLC

Forward Citations = 1,049

46 inventors:

John A Latham (69 out of 125 patents)

Jeffrey T L Smith (67 out of 95 patents)

Leon F Garcia-Martinez (59 out of 89 patents)

4. Benjamin H Dutzar (44 out of 72 patents)

5. Ethan Wayne Ojala (37 out of 65 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Alderbio Holdings LLC. Retrieved from https://idiyas.com/company/alderbio-holdings

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…